Clinical Trial Unit

The Ziauddin Clinical Trial Unit is dedicated to conducting high-quality clinical trials across various therapeutic areas, adhering to international regulatory standards, and collaborating with researchers, clinicians, and industry partners. It serves as a dynamic hub where healthcare professionals, researchers, and industry experts collaborate to address crucial medical challenges and drive medical advancements. Equipped with cutting-edge infrastructure, dedicated facilities, and advanced technology, the CTU provides an optimal environment for rigorous trial execution and reliable clinical data generation. Upholding ethical guidelines, regulatory compliance, and participant safety is paramount, fostering trust among participants, sponsors, and the wider medical community. Through this prospectus, the CTU invites researchers, sponsors, and industry partners to collaborate and leverage its resources, offering comprehensive services throughout the clinical trial lifecycle. With a vision to contribute to scientific discoveries, enhance patient care, and shape the future of medical research and innovation, the Ziauddin Clinical Trial Unit aims to be at the forefront of clinical research.

The Clinical Trial Unit at Ziauddin was established in 2022 and holds recognition from the Drug Regulatory Authority of Pakistan (DRAP). This recognition by DRAP highlights the unit’s compliance with regulatory standards and its commitment to conducting clinical trials in accordance with national guidelines. As an officially recognized clinical trial unit, Ziauddin is well-positioned to contribute to the advancement of medical research and innovation in Pakistan. By adhering to DRAP regulations, the unit ensures that all trials conducted within its facilities follow the necessary ethical and safety guidelines, thereby maintaining the integrity of the research process and protecting the well-being of trial participants.

The Clinical Trial Unit at Ziauddin aims to conduct high-quality clinical trials, develop innovative therapies, contribute to evidence-based medicine, enhance patient care, and foster a culture of research and innovation among healthcare professionals.

Welcome to the Ziauddin University Clinical Trials Unit website. At Ziauddin University, we are committed to providing excellence in clinical research and evidence-based interventions, which is why we are proud to introduce our Clinical Trials Unit. By leveraging the expertise of our faculty and staff, the Clinical Trials Unit provides our university community with a state-of-the-art platform for conducting clinical trials. We are dedicated to providing the highest quality research services and resources to our clients and partners. The Clinical Trials Unit is committed to helping our partners achieve their research goals while working in a safe, secure, and compliant environment. Our team of dedicated professionals is available to answer questions and provide guidance to ensure that clinical trials are conducted in accordance with the highest ethical standards. We invite you to explore our website to learn more about the Clinical Trials Unit and its services. We look forward to working with you to advance the science of clinical research and evidence-based interventions.


Dr.Nida Hussain
CEO Clinical Trial Unit
Ziauddin University

Mission: To execute clinical trials effectively and competently in clinical research in line with the International Directives for Clinical Trial Research (Declaration of Helsinki, ICH, and GCP Guidelines).

Vision:  The Clinical Trials Unit aims to conduct clinical trials that help Sponsors and collaborators to develop new medications and new indications for existing medications for a variety of disorders over a wide spectrum of clinical areas. At the same time, helping our patients and clinical trial participants discover new and effective therapies for their conditions where other existing therapies have been unsuccessful.

Dr. Nida Hussain

CEO [email protected]

Dr.Zulfiqar Ali Umrani

Director Admin/ORIC [email protected]

Dr. Madiha Hashmi

Director Clinical Operations [email protected]

Dr. Mirza Tasawer Baig

Director Regulatory Affair [email protected]

Dr. Ashok Kumar

Co-Director Clinical Operations [email protected]

Mansoor Ahmer Khan

Manager CTU [email protected]

Ms. Sidra Tayyab

Manager Quality Assurance [email protected]

Dr. Sana Ansari

Manager Quality Control

Ms. Sana Kanwal

Manager Medical Record [email protected]

Mr. Fahad Ali

Manager IT [email protected]

Dr. Farah Naz

Clinical Pharmacist [email protected]

Ms. Aasma Moin Khan

Study Coordinator [email protected]

Dr. Arishay Hussaini

Study Coordinator [email protected]

Mr. Adnan Gul

Data Entry Officers

Mr. Akash Thakrani

Data Entry Officers

  • Equipped examination rooms, consultation rooms, Separate Consent room and assessment rooms

  • Infusion and cardiac monitoring

  • Protocol-related specimen collection, processing, and handling; specimen collection restrooms

  • Management of experimental products linked to protocols

  • Dedicated space for investigators to work during research clinics

  • Reception, check-in, and waiting area

  • Nutrition support – study subjects, approved access per protocol (fasting, long-stay)

  • Safe Waste Disposal

  • Standard – bed Units with oxygen, vacuum; infusion pumps, and vitals monitors

  • -20C & -80C freezer’s

  • On-site ECG tracing services and Cardiac monitoring capability

  • Equipped and medically stocked emergency cart

  • Audio and visual call system

  • All clinical and consulting rooms are provided with a wireless Internet connection and secure Computers and computer systems.

  • Audio-conference facilities to facilitate collaborations

  • workspaces for study coordinators

  • Procedure room with four beds, an emergency trolley, and IV infusion supplies

  • Secure Document/data storage room

  • Data entry and data management services

  • Support services – printing, copying, and other

  • Specialized monitoring area

  • Hazard monitoring command center

  • Fire emergency system (Fire Alarm, Fire extinguisher and Fire proof cabinets)


Clinically-Oriented Antimicrobial Resistance Surveillance
Network for Healthcare-associated

(Funded by National University of Singapore/Wellcome Trust)


Genetics of Mortality in Critical Care

(Funded by University of Edinburgh)


Enabling ISARIC Clinical Characterization Protocol (CCP) rollout in LMICs

(Funded by University of Oxford/Wellcome Trust)

MM Vs. N95

Medical Masks versus N95 respirators to prevent 2019 Novel Coronavirus Disease (COVID-19 N95 Vs MM)

(Funded by McMaster University)


The Mega Randomized Registry Trial Comparing Conservative vs. Liberal Oxygenation Targets

(Funded by MRINZ )


Oxygen requirements and approaches to respiratory support in patients with COVID-19 in low- and middle-income

(Funded by WHO)


Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia including COVID 19
(REMAP CAP+ Pandemic) in Pakistan.

(Funded by Monash University)


Randomized Evaluation of COVID-19 Therapy

ISRCTN: ISRCTN50189673 EU Clinical Trials Register: EudraCT 2020-001113-21

Clinical Trials.gov: NCT04381936 RECOVERY)

(Funded by University of Oxford)

Sr. No

Trial TitlePrincipal InvestigatorCo-Principal InvestigatorFunding AmountStatus
1A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19Dr. Nida HussainDr. Ashok Kumar$110,000Starting in July
2A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast CancerDr. Adnan Abdul JabbarN/A$330,000Recently approved
3A Phase III, Randomized, Comparator-Controlled, Double-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Lot to Lot Consistency of Three Lots of a PIKA Rabies Vaccine (Vero cell) for human use, freeze-dried in Healthy Adults using a Post Exposure Prophylaxis ScheduleDr. Osama Rehman KhalidDr. Ashok Kumar$375,000Sponsor visit in July
4A Phase 2, Open-Label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic Hepatitis C Virus (HCV) InfectionDr. Zaigham AbbasN/A$100,000Expected enrollment to start by August
5A multicenter, open-label, randomized, phase III clinical trial to evaluate efficacy and safety of XXX versus imatinib at 600 or 800 mg daily in adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase (CP) resistant to imatinib at daily doses of 400 or 600 mgDr. Amna Qamar us ZamanN/A$90,000Recently conducted site selection visit
6A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitisDr. Zaigham AbbasN/ATBDTBD
7Evaluating the use of an FDA cleared, novel vaginal speculum for gynecologic proceduresDr. Rubina HussainDr. Fatima Jehangir$1,500Study completed
8A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy with BCD-264 and Darzalex® in Subjects with Relapsed and Refractory Multiple MyelomaDr. Amna Qamar Us ZamanN/ATBDSite selection visit pending
9A Phase 3 study, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of investigational Influenza Vaccine Compared to a High-Dose Quadrivalent Influenza Vaccine (Fluzone HD) in adults ≥ 65 Years of AgeDr. Abbas ZafarDr. Uzma GhouriTBDSite selection visit pending
10Multicenter, randomized, controlled, open-label, phase IIb study to assess efficacy and safety of HH-003 injection in subjects with chronic hepatitis delta virus infectionDr. Zaigham AbbasN/ATBDSite has been selected
11Enabling ISARIC Clinical Characterization Protocol (CCP) rollout in LMICs ISARIC funded by University of Oxford/Wellcome TrustDr. Madiha HashmiN/AGBP    48,674.08Successfully going to end by 2023
12The Mega Randomized Registry Trial Comparing Conservative vs. Liberal Oxygenation Targets (Mega-ROX) funded by MRINZDr. Madiha HashmiN/ATBDStudy on going
13Randomized Evaluation of COVID-19 Therapy ISRCTN: ISRCTN50189673 EU Clinical Trials Register: EudraCT 2020-001113-21 Clinical Trials.gov: NCT04381936 RECOVERY) funded by University of OxfordDr. Madiha HashmiN/APKR 1,239,290 Study completed
14Medical Masks versus N95 respirators to prevent 2019 Novel Coronavirus Disease (COVID-19 N95 Vs MM) funded by McMaster UniversityDr. Madiha HashmiN/A$ 205,700Study completed
15Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia including COVID 19 (REMAP CAP+ Pandemic) in Pakistan (REMAP-CAP) funded by Monash UniversityDr. Madiha HashmiN/AAUD 83,142.40Study completed
16Oxygen requirements and approaches to respiratory support in patients with COVID-19 in low- and middle-income countries (O2CoV2) funded by WHODr. Madiha HashmiN/A$ 10,901Study completed
17Clinically-Oriented Antimicrobial Resistance Surveillance Network for Healthcare-associated (ACORN-HAI) funded by National University of Singapore / Wellcome TrustDr. Osama Rehman KhalidN/ASGD 79,530Patient enrollment is ongoing
18Genetics of Mortality in Critical Care (GenOMICC) funded by University of EdinburghDr. Madiha HashmiN/ATBDStudy on going


+9221-35862937 ext 2359


Ziauddin University,  4/B, Shahrah-e-Ghalib, Block 6, Clifton Karachi.


[email protected]